GSK is acquiring 35Pharma for $950 million, and getting rights to HS235, a potential best-in-class PH treatment now in early clinical testing.

Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.

LONDON — Building up its base of medicines for lung diseases, GSK said Wednesday it was buying the privately held firm 35Pharma for $950 million in cash. The centerpiece of the deal is an experimental ...

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary ...

Pulmonary hypertension is a serious condition that happens when the blood pressure in the arteries of the lungs is higher ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Higher blood levels of allergy molecule IgE were associated with worsening right heart function in people with PAH, a study in China found.

Early signs of pulmonary hypertension are relatively mild and mimic common conditions such as asthma, poor fitness or anxiety. [Courtesy] Many people are familiar with hypertension, commonly described ...